Cancers, Vol. 12, Pages 686: Pathogenesis and Clinical Management of Uterine Serous Carcinoma

Cancers, Vol. 12, Pages 686: Pathogenesis and Clinical Management of Uterine Serous Carcinoma Cancers doi: 10.3390/cancers12030686 Authors: Li Zhang Suet Ying Kwan Kwong Kwok Wong Pamela T. Solaman Karen H. Lu Samuel C. Mok Uterine serous carcinoma (USC) is an aggressive variant of endometrial cancer that has not been well characterized. It accounts for less than 10% of all endometrial cancers and 80% of endometrial cancer–related deaths. Currently, staging surgery together with chemotherapy or radiotherapy, especially vaginal cuff brachytherapy, is the main treatment strategy for USC. Whole-exome sequencing combined with preclinical and clinical studies are verifying a series of effective and clinically accessible inhibitors targeting frequently altered genes, such as HER2 and PI3K3CA, in varying USC patient populations. Some progress has also been made in the immunotherapy field. The PD-1/PD-L1 pathway has been found to be activated in many USC patients, and clinical trials of PD-1 inhibitors in USC are underway. This review updates the progress of research regarding the molecular pathogenesis and putative clinical management of USC.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research